2,060
Views
7
CrossRef citations to date
0
Altmetric
Report

T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways

, , , &
Pages 1003-1017 | Received 01 May 2018, Accepted 17 Jul 2018, Published online: 11 Sep 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Alexis Q. Dean, Shen Luo, Julianne D. Twomey & Baolin Zhang. (2021) Targeting cancer with antibody-drug conjugates: Promises and challenges. mAbs 13:1.
Read now
Nishant Mohan, Salman Hosain, Jun Zhao, Yi Shen, Xiao Luo, Jiangsong Jiang, Yukinori Endo & Wen Jin Wu. (2019) Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells. OncoImmunology 8:9.
Read now

Articles from other publishers (4)

Elena Díaz-Rodríguez, Lucía Gandullo-Sánchez, Alberto Ocaña & Atanasio Pandiella. (2021) Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers 14:1, pages 154.
Crossref
Lucía Gandullo-Sánchez, Alberto Ocaña & Atanasio Pandiella. (2021) Generation of Antibody-Drug Conjugate Resistant Models. Cancers 13:18, pages 4631.
Crossref
Simmyung Yook, Zhongli Cai, Jenny Jooyoung Jeong, Yijie Lu, Mitchell A. Winnik, Jean-Philippe Pignol & Raymond M. Reilly. (2020) Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177 Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines . Molecular Pharmaceutics 17:4, pages 1226-1236.
Crossref
Elisabete Cruz da Silva, Monique Dontenwill, Laurence Choulier & Maxime Lehmann. (2019) Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer. Cancers 11:5, pages 692.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.